Patent · US Active

Aurora A kinase inhibitor

US9637474B2 · kind B2 · utility

0Cited by
2References
6Claims
0Family size

Assignee

Inventor

Key dates

Filing dateNov 6, 2015
Grant dateMay 2, 2017
Priority date
Expiry dateNov 6, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D401/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.